Johnson & Johnson (JNJ)

142.22
1.77 1.26
NYSE : Health Technology
Prev Close 140.45
Open 141.25
Day Low/High 141.00 / 142.31
52 Wk Low/High 120.11 / 148.99
Volume 2.93M
Avg Volume 6.49M
Exchange NYSE
Shares Outstanding 2.66B
Market Cap 372.32B
EPS 5.70
P/E Ratio 25.97
Div & Yield 3.80 (2.62%)

Latest News

Good Value or Value Trap?: Cramer's 'Mad Money' Recap (Wednesday 6/12/19)

Good Value or Value Trap?: Cramer's 'Mad Money' Recap (Wednesday 6/12/19)

Jim Cramer says spotting the bottom is really tough; and if you're too early, you'll get hit hard.

Jim Cramer: A Tale of Two Stocks

Jim Cramer: A Tale of Two Stocks

I want you to remember Eli Lilly and Johnson & Johnson the next time you are about to dump a stock because of some bits of bad news.

Weekly Roundup

Markets surge in face of multiple uncertainties.

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Thursday 6/6/19)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Thursday 6/6/19)

Jim Cramer says it's extremely important to buy stocks that are exactly right for you and your level of risk tolerance.

Trimming a Healthcare Name for a Large Gain

We think Abbott Labs is a terrific company, but the stock already has a big premium and that may limit the potential of future gains.

Johnson & Johnson Releases 2018 Health For Humanity Report

Johnson & Johnson Releases 2018 Health For Humanity Report

Sharing Progress in Environmental, Social and Governance Practices

MyPhillyLawyer Helps Secure $80 Million Victory For Transvaginal Mesh Patient

MyPhillyLawyer Helps Secure $80 Million Victory For Transvaginal Mesh Patient

PHILADELPHIA, June 3, 2019 /PRNewswire/ -- A Philadelphia jury awarded more than $80 million to a 75-year-old woman in a transvaginal mesh lawsuit against Ethicon, a subsidiary of Johnson & Johnson (NYSE: JNJ).

Last Week's Portfolio Changes

We initiated a new position in Mastercard and made several ratings and price target changes.

Johnson & Johnson: Follow Warren Buffett's Advice and Be Greedy

Johnson & Johnson: Follow Warren Buffett's Advice and Be Greedy

Overblown litigation concerns have scared off many investors, making now a good time to buy.

Weekly Roundup

Rough week for stocks capped by new front in tariff wars with Mexico.

Buying Back Shares in a Semi Equipment Maker Stock We Recently Sold Higher

We are adding to our Lam Research position.

Johnson & Johnson Ordered to Pay $300 Million Punitive Award in Talc Case

Johnson & Johnson Ordered to Pay $300 Million Punitive Award in Talc Case

Johnson & Johnson is ordered to pay a $300 million punitive award to a woman who said she contracted cancer through the use of the company's talc-based products.

Video: Jim's Daily Rundown for Thursday

Jim gives his view on an analyst take that Cisco is a "relative safe haven in this macro backdrop," he provides thoughts on Palo Alto Networks, he discusses Viacom, and much more!

Jim Cramer: This Is Now an Emotional Market

Jim Cramer: This Is Now an Emotional Market

When traders are flailing and investors are drowning, examples work best to illustrate what happens before a bottom is reached.

It's Getting Emotional: Cramer's 'Mad Money' Recap (Wednesday 5/29/19)

It's Getting Emotional: Cramer's 'Mad Money' Recap (Wednesday 5/29/19)

The current selloff is finally starting to prompt overwrought responses from investors, Jim Cramer says.

Buffett's Berkshire Hathaway Closes Below $300,000

Buffett's Berkshire Hathaway Closes Below $300,000

Shares of Warren Buffett's investment vehicle, Berkshire Hathaway, ended the day below $300,000 for the first time since late March.

Stocks Slide as Bond Yields Tumble, China Threatens Rare Earths Ban

Stocks Slide as Bond Yields Tumble, China Threatens Rare Earths Ban

Stocks tumble Wednesday as falling bond yields and a rare earth ban threat by China rattle Wall Street.

Markets Slumping Wednesday but Our Cash Allows Us to Be Opportunistic

Our 'stay the course' plan during these moments is to use scale and look to buy high-quality merchandise (stocks) that we previously sold higher and are now trading at a discount.

TheStreet Quant Rating: B (Buy)